NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $1.75 -0.07 (-3.85%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.71 -0.04 (-2.51%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Karyopharm Therapeutics Stock (NASDAQ:KPTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KPTI alerts:Sign Up Key Stats Today's Range$1.66▼$1.8450-Day Range$1.54▼$9.5152-Week Range$1.24▼$10.99Volume957,447 shsAverage Volume1.38 million shsMarket Capitalization$39.69 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on nuclear transport, particularly the role of exportin 1 (XPO1) in regulating the movement of proteins and RNA between a cell’s nucleus and cytoplasm. Karyopharm’s primary product is selinexor, an oral selective inhibitor of XPO1. In the United States, selinexor is marketed as XPOVIO for certain patients with multiple myeloma and diffuse large B-cell lymphoma, in combination with specified therapies or under defined treatment circumstances. The company continues to study selinexor in additional hematologic malignancies and solid tumors, as well as in combination with other cancer treatments. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built its business around its proprietary Selective Inhibitor of Nuclear Export platform. The company serves patients primarily through its commercial operations in the United States and through international partnerships and licensing arrangements. Outside the United States, selinexor is marketed in certain territories under the name NEXPOVIO by Menarini Group companies.AI Generated. May Contain Errors. Read More Karyopharm Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreKPTI MarketRank™: Karyopharm Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 531st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKaryopharm Therapeutics has a consensus price target of $11.50, representing about 557.1% upside from its current price of $1.75.Amount of Analyst CoverageKaryopharm Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($4.70) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted44.01% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 9.35.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 1.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Karyopharm Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows4 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38.00 in company stock.Percentage Held by Insiders1.68% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPTI Stock News HeadlinesBioAge Labs (NASDAQ:BIOA) and Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head ReviewSeptember 21 at 8:59 AM | americanbankingnews.comKaryopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial UpdatesSeptember 4, 2026 | finance.yahoo.comHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its valuation has doubled since the announcement, with some estimates putting the company's worth near 3 trillion dollars by IPO day. Google, Amazon, Nvidia and Microsoft have all taken stakes, while Goldman Sachs, Morgan Stanley and JPMorgan are competing for private shares. Anthropic's annualized revenue reportedly grew 80 times in the first quarter alone. See how investors are positioning ahead of this closely watched IPO. | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)September 3, 2026 | theglobeandmail.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | prnewswire.comKaryopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisAugust 31, 2026 | finanznachrichten.deKaryopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With RuxolitinibAugust 31, 2026 | rttnews.comKaryopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock UpAugust 31, 2026 | rttnews.comSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $7.36 at the beginning of 2026. Since then, KPTI stock has decreased by 76.2% and is now trading at $1.75. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.37) by $0.95. The firm had revenue of $33.43 million for the quarter, compared to the consensus estimate of $32.19 million. Read the conference call transcript. When did Karyopharm Therapeutics' stock split? Shares of Karyopharm Therapeutics reverse split on Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Karyopharm Therapeutics IPO? Karyopharm Therapeutics (KPTI) raised $102 million in an initial public offering (IPO) on Wednesday, November 6th 2013. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. Who are Karyopharm Therapeutics' major shareholders? Top institutional investors of Karyopharm Therapeutics include Squarepoint Ops LLC (0.28%), Bank of New York Mellon Corp (0.25%), Engineers Gate Manager LP (0.15%) and Headlands Technologies LLC (0.05%). Insiders that own company stock include Stuart Poulton, Richard A Paulson, Reshma Rangwala, Sohanya Roshan Cheng, Michael Mason, Kristin Abate and Michael Mano. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS). Company Calendar Last Earnings8/13/2026Today9/23/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KPTI's financial health is in the Red zone, according to TradeSmith. KPTI has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPTI CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees228Year Founded2008Price Target and Rating Average Price Target for Karyopharm Therapeutics$11.50 High Price Target$28.00 Low Price Target$3.00 Potential Upside/Downside+557.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($13.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.04 million Net Margins-153.28% Pretax Margin-153.30% Return on EquityN/A Return on Assets-145.18% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.76 Sales & Book Value Annual Sales$146.07 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value($16.00) per share Price / Book-0.11Miscellaneous Outstanding Shares22,680,000Free Float22,300,000Market Cap$39.69 million OptionableOptionable Beta0.95 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:KPTI) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhat the Iran War Is Really AboutTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPTI Stock Alerts